Martin-Grau M, Monleon D. Sex dimorphism and metabolic profiles in management of metabolic-associated fatty liver disease. World J Clin Cases 2023; 11(6): 1236-1244 [PMID: 36926130 DOI: 10.12998/wjcc.v11.i6.1236]
Corresponding Author of This Article
Daniel Monleon, PhD, Professor, Department of Pathology, University of Valencia, Avenue Blasco Ibañez, 15, Valencia 46010, Spain. daniel.monleon@uv.es
Research Domain of This Article
Biochemistry & Molecular Biology
Article-Type of This Article
Minireviews
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Clin Cases. Feb 26, 2023; 11(6): 1236-1244 Published online Feb 26, 2023. doi: 10.12998/wjcc.v11.i6.1236
Sex dimorphism and metabolic profiles in management of metabolic-associated fatty liver disease
Maria Martin-Grau, Daniel Monleon
Maria Martin-Grau, Daniel Monleon, Department of Pathology, University of Valencia, Valencia 46010, Spain
Author contributions: Martin-Grau M and Monleon D contributed to writing and revising; All authors have read and approved the final manuscript.
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Daniel Monleon, PhD, Professor, Department of Pathology, University of Valencia, Avenue Blasco Ibañez, 15, Valencia 46010, Spain. daniel.monleon@uv.es
Received: September 20, 2022 Peer-review started: September 20, 2022 First decision: October 18, 2022 Revised: November 30, 2022 Accepted: February 2, 2023 Article in press: February 2, 2023 Published online: February 26, 2023
Core Tip
Core Tip: Metabolic-associated fatty liver disease (MAFLD) refers to the build-up of fat in the liver associated with metabolic dysfunction and has been estimated to affect a quarter of the population worldwide. Metabolomics represents a powerful approach to studying metabolic disease, including MAFLD, and to identify potential biomarkers and putative mechanisms. Some studies demonstrate associations between circulating metabolites and early and established MAFLD, but little is known about how metabolites relate to and encompass sex differences in disease progression and risk management. In this review, we will discuss the role of metabolic profiles in understanding mechanisms and identifying sex-dependent biomarkers, and how this evidence may help in the future management of the disease.
